StockData
Cogent Biosciences, Inc. logo

Cogent Biosciences, Inc. (COGT) company profile

COGTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 2/30
$27.85+0.41 (+1.49%)

Close on Nov 17, 2026Market cap $4.83BP/E –Yield –

About Cogent Biosciences

Pharmaceutical Preparations, SIC 2834

Cogent Biosciences, Inc. is a biotechnology company focused on discovering and developing therapeutic drug candidates. The company's principal development program centers on bezuclastinib, a targeted product candidate undergoing clinical trials, alongside several early-stage discovery and preclinical research programs. Cogent Biosciences designs its drug candidates to address specific clinical conditions, targeting patient populations in need of novel treatments. The company aims to provide its therapies to healthcare providers, physicians, patients, and third-party healthcare payors upon receiving necessary regulatory approvals.

The company is incorporated in Delaware and maintains its corporate headquarters in Waltham, Massachusetts. Its physical footprint includes leased office and laboratory facilities located in Waltham, Massachusetts, and Boulder, Colorado. Cogent Biosciences conducts its drug development operations primarily in the United States, coordinating clinical trials, regulatory submissions, and research activities with regulatory authorities such as the Food and Drug Administration.

Summary of the business section of Cogent Biosciences's latest annual report, written by StockData.

Company profile

Company

Legal name
Cogent Biosciences, Inc.
Founded
2014
Headquarters
Waltham, MA
Address
180 Third Avenue, 4th Floor
Phone
(617) 945-5576
Employees
258, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
PricewaterhouseCoopers LLP, Boston, Massachusetts

Stock & identifiers

Ticker
COGT
Former tickers
UMRX until Nov 9, 2020
Exchange
Nasdaq
IPO date
Mar 29, 2018
Shares outstanding
174M, Aug 6, 2026
Public float
$772.90M, Jun 30, 2025
Filer category
Large accelerated filer
Stock splits
1-for-4 reverse, Nov 9, 2020
SEC CIK
1622229
CUSIP
19240Q201
ISIN
US19240Q2012
FIGI
BBG007DHZQR7
Share class FIGI
BBG007DHY102
EIN
46-5308248

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Andrew R. RobbinsPresident and CEO, Director657,503
Evan KearnsChief Legal Officer109,398
John Edward RobinsonChief Scientific Officer140,002
Jessica SachsChief Medical Officer133,938
John L. GreenChief Financial Officer131,834
Cole PinnowChief Commercial Officer97,450
Karen Jean FerranteDirector–
Arlene MorrisDirector45,510
Christopher W. CainDirector–
Matthew RosDirector–
Todd ShegogDirector–
Peter Evan HarwinDirector–
Funds Management LLC FairmountDirector5,503,418

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$27.76M$116.77M$8.93M$414$121
FY2024$4.92M$11.88M$2.34M$91$91
FY2023$7.90M-$201.50K$2.99M$69$92
FY2022$4.39M$9.82M$1.89M$135$89

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsIncentive payOtherTotalvs. prior year
Andrew Robbins
Chief Executive Officer
$724.55K$21.60K$12.99M$13.45M$561.60K$14.00K$27.76M+465%
John Green
Chief Financial Officer
$510.68K$11.47K$3.97M$3.75M$298.13K$14.00K$8.55M+389%
Jessica Sachs
Chief Medical Officer
$549.39K$12.34K$4.54M$3.75M$320.89K$14.00K$9.18M+401%
Cole Pinnow
Chief Commercial Officer
$482.27K$9.57K$4.54M$3.55M$248.77K$14.00K$8.84M+123%
John Robinson
Chief Scientific Officer
$532.04K$11.95K$4.54M$3.75M$310.76K$14.00K$9.15M+406%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Mar 29, 2018
Offer price
$12.00
Securities offered
5,770,000
Gross proceeds
$69.24M
Exchange
Nasdaq
First trading day
Mar 29, 2018
First-day close
$11.11-7.4%
Lock-up ends (est.)
Sep 25, 2018

“The initial public offering price per share of our common stock is $12.00.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 258 employees.”

Corporate history

Events identified from SEC filings

DateEventDetails
Oct 9, 2020Merger voteDefinitive merger proxy statement
Oct 5, 2020Name changeName changed from Unum Therapeutics Inc. to Cogent Biosciences, Inc.
Sep 3, 2020Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jul 6, 2020Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jan 6, 2020Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Mar 29, 2018IPOInitial public offering priced (424B4 prospectus)
Mar 26, 2018ListingRegistration of securities on an exchange (Form 8-A)

See a number that looks wrong?